Movement Alert｜DUALITYBIO-B Falls 5.18% in Regular Trading, Hong Kong Biotech Sector Under Pressure

Market Focus10-13

On October 13, DUALITYBIO-B fell 5.18% in regular trading, trading at 170.3 Hong Kong dollars per share, with turnover of 17.8155 million Hong Kong dollars. The decline was in line with broad weakness across the Hong Kong biotech sector, as several peers also traded lower during the session.

Within the biotechnology sector where DUALITYBIO-B belongs, the overall sector performance was weak. Among individual stocks, AKESO fell 4.2%, INNOVENT BIO fell 2.28%, BEONE MEDICINES fell 2.17%, METIS TECHBIO-P fell 10.11%, and 3SBIO fell 1.56%.

DUALITYBIO-B is an investment holding company mainly engaged in clinical-stage biopharmaceuticals. It is dedicated to developing antibody-drug conjugate (ADC) innovative drugs for cancer and autoimmune diseases. Its main candidates include DB-1303/BNT323, DB-1311/BNT324, DB-1310, DB-1305/BNT325, DB-1419, and DB-2304. These products primarily target endometrial cancer, breast cancer, small cell lung cancer, castration-resistant prostate cancer, esophageal squamous cell carcinoma, and head and neck squamous cell carcinoma. The company operates mainly in domestic and international markets.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1162795180?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-10-13 09:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1162795180","market":"us","top_or_hot":-1,"title":"Movement Alert｜DUALITYBIO-B Falls 5.18% in Regular Trading, Hong Kong Biotech Sector Under Pressure","media":"Market Focus","content":"<p><p>On October 13, DUALITYBIO-B fell 5.18% in regular trading, trading at 170.3 Hong Kong dollars per share, with turnover of 17.8155 million Hong Kong dollars. The decline was in line with broad weakness across the Hong Kong biotech sector, as several peers also traded lower during the session.</p><p>Within the biotechnology sector where DUALITYBIO-B belongs, the overall sector performance was weak. Among individual stocks, AKESO fell 4.2%, INNOVENT BIO fell 2.28%, BEONE MEDICINES fell 2.17%, METIS TECHBIO-P fell 10.11%, and 3SBIO fell 1.56%.</p><p>DUALITYBIO-B is an investment holding company mainly engaged in clinical-stage biopharmaceuticals. It is dedicated to developing antibody-drug conjugate (ADC) innovative drugs for cancer and autoimmune diseases. Its main candidates include DB-1303/BNT323, DB-1311/BNT324, DB-1310, DB-1305/BNT325, DB-1419, and DB-2304. These products primarily target endometrial cancer, breast cancer, small cell lung cancer, castration-resistant prostate cancer, esophageal squamous cell carcinoma, and head and neck squamous cell carcinoma. The company operates mainly in domestic and international markets.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜DUALITYBIO-B Falls 5.18% in Regular Trading, Hong Kong Biotech Sector Under Pressure</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜DUALITYBIO-B Falls 5.18% in Regular Trading, Hong Kong Biotech Sector Under Pressure\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-10-13 09:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On October 13, DUALITYBIO-B fell 5.18% in regular trading, trading at 170.3 Hong Kong dollars per share, with turnover of 17.8155 million Hong Kong dollars. The decline was in line with broad weakness across the Hong Kong biotech sector, as several peers also traded lower during the session.</p><p>Within the biotechnology sector where DUALITYBIO-B belongs, the overall sector performance was weak. Among individual stocks, AKESO fell 4.2%, INNOVENT BIO fell 2.28%, BEONE MEDICINES fell 2.17%, METIS TECHBIO-P fell 10.11%, and 3SBIO fell 1.56%.</p><p>DUALITYBIO-B is an investment holding company mainly engaged in clinical-stage biopharmaceuticals. It is dedicated to developing antibody-drug conjugate (ADC) innovative drugs for cancer and autoimmune diseases. Its main candidates include DB-1303/BNT323, DB-1311/BNT324, DB-1310, DB-1305/BNT325, DB-1419, and DB-2304. These products primarily target endometrial cancer, breast cancer, small cell lung cancer, castration-resistant prostate cancer, esophageal squamous cell carcinoma, and head and neck squamous cell carcinoma. The company operates mainly in domestic and international markets.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09606","symbol_name":"映恩生物-B","start_time":0,"source_url":"","article_id":"1162795180","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1162795180","pubTimestamp":1791856217,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On October 13, DUALITYBIO-B fell 5.18% in regular trading, trading at 170.3 Hong Kong dollars per share, with turnover of 17.8155 million Hong Kong dollars. The decline was in line with broad...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09606":"映恩生物-B"},"translate_title":"走势警报|DUALITYBIO-B常规交易下跌5.18%，香港生物科技板块承压","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09606":1},"content_text":"On October 13, DUALITYBIO-B fell 5.18% in regular trading, trading at 170.3 Hong Kong dollars per share, with turnover of 17.8155 million Hong Kong dollars. The decline was in line with broad weakness across the Hong Kong biotech sector, as several peers also traded lower during the session.Within the biotechnology sector where DUALITYBIO-B belongs, the overall sector performance was weak. Among individual stocks, AKESO fell 4.2%, INNOVENT BIO fell 2.28%, BEONE MEDICINES fell 2.17%, METIS TECHBIO-P fell 10.11%, and 3SBIO fell 1.56%.DUALITYBIO-B is an investment holding company mainly engaged in clinical-stage biopharmaceuticals. It is dedicated to developing antibody-drug conjugate (ADC) innovative drugs for cancer and autoimmune diseases. Its main candidates include DB-1303/BNT323, DB-1311/BNT324, DB-1310, DB-1305/BNT325, DB-1419, and DB-2304. These products primarily target endometrial cancer, breast cancer, small cell lung cancer, castration-resistant prostate cancer, esophageal squamous cell carcinoma, and head and neck squamous cell carcinoma. The company operates mainly in domestic and international markets.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1162795180","isCrawlerRequest":true}